Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

DISEASE CHARACTERISTICS: * Histologically confirmed advanced malignancy, including the following: * Solid tumor that is refractory to standard therapy or for which no standard therapy exists * No lung carcinoma of squamous cell or small cell histology (mixed tumors will be categorized by the predominant cell type) * Histological confirmation based on sputum cytology alone is not acceptable * Lymphoma (Hodgkin or non-Hodgkin lymphoma) that has progressed after standard therapy AND for which stem cell transplantation is not indicated or has been refused * No known CNS disease, except for treated brain metastasis meeting the following criteria: * No ongoing requirement for steroids * No evidence of progression or hemorrhage by clinical examination and brain imaging (MRI or CT scan) for ≥ 3 months after treatment * Stable dose of anticonvulsants allowed * Prior treatment for brain metastases may have included whole-brain radiotherapy, radiosurgery (gamma knife, linear accelerator, or equivalent), or a combination of therapy as deemed appropriate by the treating physician * Neurosurgical resection or brain biopsy for treatment of CNS metastases allowed provided treatment was completed more than 3 months ago PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100% * Life expectancy \> 3 months * Absolute neutrophil count ≥ 1,500/μL * Platelet count ≥ 100,000/μL * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN * Creatinine \< 1.5 times ULN OR creatinine clearance ≥ 60 mL/min * Urine protein:creatinine ratio ≤ 0.5 OR urine protein \< 1,000 mg by 24-hour urine collection * Activated partial thromboplastin time ≤ 1.5 times ULN * Prothrombin time OR INR \< 1.5 times ULN * Potassium between 4 mmol/L and ULN (supplementation allowed) * Magnesium normal (supplementation allowed) * Serum calcium (adjusted for albumin) or ionized calcium normal (supplementation allowed) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy * HIV-positivity allowed provided the following criteria are met: * Patient does not require anti-HIV therapy * CD4 count \> 350/mm\^3 * HIV viral load \< 25,000 copies/mm\^3 * No history of opportunistic infections * No evidence of severe or uncontrolled systemic disease or any concurrent condition that could compromise participation in the study, including any of the following: * Active or uncontrolled infection * Immune deficiencies * HIV infection requiring anti-HIV therapy * Hepatitis B * Hepatitis C * Uncontrolled diabetes * Uncontrolled hypertension * Symptomatic congestive heart failure * Unstable angina pectoris * Myocardial infarction within the past 6 months * Uncontrolled cardiac arrhythmia * Stroke/cerebrovascular accident within the past 6 months * Psychiatric illness/social situation that, in the investigator's opinion, would make it undesirable for the patient to participate in the study or that would jeopardize study compliance * No New York Heart Association class III or IV heart disease within the past 6 months * No history of arrhythmia (i.e., multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment * Atrial fibrillation allowed provided it is controlled with medication * No asymptomatic sustained ventricular tachycardia * No other cardiac disease that, in the investigator's opinion, would increase the risk of ventricular arrhythmia * QTc \< 480 msec (with measurable Bazett correction) by screening ECG * No history of QTc prolongation as a result of other medications that required discontinuation * No congenital long QT syndrome * No first-degree relative with unexplained sudden death at under 40 years of age * No left bundle branch block * No hypertension not controlled by medical therapy, defined as systolic blood pressure \> 150 mm Hg or diastolic blood pressure \> 90 mm Hg despite optimal medical management * No other clinically significant cardiac event * No thromboembolic disease within the past 6 months * No significant vascular disease (e.g., aortic aneurysm or aortic dissection) or clinically significant peripheral vascular disease * No serious non-healing wounds (including wounds healing by secondary intention) * No acute or non-healing ulcers * No bone fractures within the past 3 months * No abdominal fistula, gastointestinal perforation, or intra-abdominal abscess within the past 28 days * No currently active diarrhea that may affect the ability of the patient to absorb or tolerate vandetanib * No hemoptysis (bright red blood of ≥ ½ teaspoon per episode) within the past 3 months * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Prior anti-VEGF therapy allowed * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy and recovered * More than 4 weeks since prior major surgery and recovered * At least 2 weeks since prior investigational drugs given in a phase 0 clinical trial * More than 10 days since prior and no concurrent aspirin (\> 325 mg/day) or chronic use of other NSAIDs * No concurrent regular, therapeutic anticoagulation * No concurrent medication that may cause QTc prolongation, induce Torsades de Pointes, or induce CYP3A4 function, including any of the following: * Rifampin * Rifabutin * Phenytoin * Carbamazepine * Phenobarbital * Hypericum perforatum (St. John's wort) * No other concurrent antineoplastic therapy, except for gonadotropin-releasing hormone therapy for prostate cancer